Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$7.27M+113.78%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Maher Masoud
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 91
- Beta
- 1.53
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.87
Financials
Revenue
$7.27M+113.8%Net Income
$-8.87MEBITDA
$-8.87MFree Cash Flow
$-4.72MEPS (diluted)
$-0.08Shares Outstanding (diluted)
106.82M+144.9%Operating Expenses
$14.88MCash & Debt
$105.69MReturn of Capital
$1.48MRevenue by Segment (annual)
$31.06MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $33.03M | $-44.63M | $-0.42 |
| 2024 | $38.63M | $-41.05M | $-0.39 |
| 2023 | $41.29M | $-37.92M | $-0.37 |
| 2022 | $44.26M | $-23.57M | $-0.19 |
| 2021 | $33.89M | $-19.08M | $-0.22 |
| 2020 | $26.17M | $-11.82M | $-0.18 |
| 2019 | $21.62M | $-12.89M | $-0.24 |
| 2018 | $16.67M | $-8.87M | $-0.17 |
| 2017 | $13.98M | $-9.92M | $-0.20 |
| 2016 | $12.27M | $-3.35M | $-0.10 |
| 2015 | $9.29M | $-1.45M | $-0.03 |
| 2014 | $7.16M | $-1.84M | $-1.59 |
| 2013 | $6.80M | $-958.2K | $-0.02 |
| 2012 | $5.06M | $-1.99M | $-0.05 |
Valuation
MXCThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-68.53%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·13d ago·Neutral
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that the Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of…
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
…NGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays. Available through MaxCyte's SeQure™ service, thes…
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
MaxCyte Q2 Earnings Call Highlights MaxCyte NASDAQ: MXCT reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year processing assembly purchases affected results. Management said the quarter came in ahead of its expectations and represented progress toward stabilizing the business before returning to growth in the second half of the year.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·54d ago·Neutral
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.12 per share a year ago.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.08 per share
Typical surprise +11.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.08 vs $-0.09beat
- Tue, May 12$-0.04 vs $-0.10beat
- Tue, Mar 24$-0.06 vs $-0.08beat
- Wed, Nov 12$-0.12 vs $-0.11miss
- Wed, Aug 6$-0.12 vs $-0.10miss
- Wed, May 7$-0.10 vs $-0.10beat
Estimates and results for MXCT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MXCT officers and directors.
- Bought
- $480k
- Sold
- $686k
5 trades
17 trades
- Swirsky Douglas Jsold
- Swirsky Douglas Jbought
- Masoud Maherbought
- Erck Stanley Cbought
- Douglas Richardbought
- Brooke William Wbought
- Hemrajani Rekhasold
- Soleymannezhad Alisold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MXCT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.